NF1 and neurofibroma: These changes in SCs may affect tumor macrophages that are wild-type at Nf1. We posited that identifying differentially expressed genes (DEGs) that comprise the pro-tumorigenic SC-macrophage interactome would provide clues to aid in development of macrophage-targeted anti-neurofibroma therapies.